We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic. The study focused on patients with Class II/III obesity and hypertension, and the results are exceptionally promising:
- Serum AGT Reduction: Sequential doses of Zilebesiran led to an impressive 99% reduction in serum angiotensinogen (AGT) levels.
- Blood Pressure Improvement: Sustained reductions in blood pressure, with a decrease of -27 ± 8 mmHg from baseline to week 24.
- Safety and Tolerance: Zilebesiran was generally well-tolerated, with only minimal adverse events reported.
These results suggest that the pharmacodynamics, efficacy, and safety of Zilebesiran may not be influenced by BMI, offering new hope in the treatment of hypertension, especially in obese patients.
For more details on this ground breaking research, please visit https://www.researchgate.net/publication/374657385_Abstract_116_Safety_And_Tolerability_Of_Zilebesiran_An_RNA_Interference_Therapeutic_Targeting_Hepatic_Angiotensinogen_Synthesis_In_Obese_Patients_With_Hypertension
NOTE: Angiotensinogen(AGT) is a protein that is part of the renin-angiotensin system. This system regulates blood pressure and the balance of fluids and salts in the body1. Angiotensinogen is produced by the liver and secreted into the bloodstream. Itis converted to angiotensin I, which is then converted to angiotensin II. Angiotensin II causes blood vessels to narrow, which results in increased blood pressure. This molecule also stimulates the production of the hormone aldosterone, which triggers the absorption of salt and water by the kidneys.